Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
EARLY SCREENING DEVICE FOR ACQUIRED RESISTANCE TO IMMUNOTHERAPY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/142244
Kind Code:
A1
Abstract:
The present application provides an early screening device for acquired resistance to immunotherapy and use thereof. The early screening device for acquired resistance to immunotherapy comprises a sequencing module, a screening module, a cluster analysis module, a monitoring module, and an analysis module. Through a comprehensive judgment based on the combination of the real-time monitoring of proportion change in cancer cell killer CD8 T cell clones in the peripheral blood with the proportion change of inexhaustible precursor T cells in the cancer cell killer CD8 T cell clones in biopsy samples, the present application can achieve very early screening of acquired resistance to immunotherapy.

Inventors:
LIU BAOLIN (CN)
ZHANG YUANYUAN (CN)
ZHANG ZEMIN (CN)
Application Number:
PCT/CN2022/081515
Publication Date:
August 03, 2023
Filing Date:
March 17, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV BEIJING (CN)
International Classes:
C12Q1/6886; C12Q1/6881; G16B30/00
Domestic Patent References:
WO2019164870A12019-08-29
Foreign References:
CN114107512A2022-03-01
CN112029858A2020-12-04
US20180066228A12018-03-08
CN111257563A2020-06-09
US20200347456A12020-11-05
CN108918847A2018-11-30
CN109777872A2019-05-21
Other References:
ZHANG YUANYUAN; CHEN HONGYAN; MO HONGNAN; HU XUEDA; GAO RANRAN; ZHAO YAHUI; LIU BAOLIN; NIU LIJUAN; SUN XIAOYING; YU XIAO; WANG YO: "Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer", CANCER CELL, CELL PRESS, US, vol. 39, no. 12, 14 October 2021 (2021-10-14), US , pages 1578, XP086898799, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2021.09.010
Attorney, Agent or Firm:
BEYOND ATTORNEYS AT LAW (CN)
Download PDF: